Figure 2.
Algorithm for consideration of HCT for SCD. Consideration of HCT and other curative therapies in individuals with SCD must take into consideration severity of disease to date, available HCT donor options, and clinical trials that an individual patient may be eligible for. While this decision-making process is complex, this algorithm provides a framework for how we consider an individual patient. Additionally, this algorithm does not take into account multiple processes that may occur concurrently, such as searching for URD and haploidentical donors, as well as considering gene therapy and mismatched related or unrelated donor HCT on a clinical trial.